Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP580212.RADVEJ-Geqysg0BWn1lDabLq8O4k10oo-Hqa4JeJcZ4iY130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP580212.RADVEJ-Geqysg0BWn1lDabLq8O4k10oo-Hqa4JeJcZ4iY130_assertion type Assertion NP580212.RADVEJ-Geqysg0BWn1lDabLq8O4k10oo-Hqa4JeJcZ4iY130_head.
- NP580212.RADVEJ-Geqysg0BWn1lDabLq8O4k10oo-Hqa4JeJcZ4iY130_assertion description "[Since TAK-652 is orally bioavailable and has favorable pharmacokinetic profiles in humans, it is considered a promising candidate for an entry inhibitor of HIV-1.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP580212.RADVEJ-Geqysg0BWn1lDabLq8O4k10oo-Hqa4JeJcZ4iY130_provenance.
- NP580212.RADVEJ-Geqysg0BWn1lDabLq8O4k10oo-Hqa4JeJcZ4iY130_assertion evidence source_evidence_literature NP580212.RADVEJ-Geqysg0BWn1lDabLq8O4k10oo-Hqa4JeJcZ4iY130_provenance.
- NP580212.RADVEJ-Geqysg0BWn1lDabLq8O4k10oo-Hqa4JeJcZ4iY130_assertion SIO_000772 17116673 NP580212.RADVEJ-Geqysg0BWn1lDabLq8O4k10oo-Hqa4JeJcZ4iY130_provenance.
- NP580212.RADVEJ-Geqysg0BWn1lDabLq8O4k10oo-Hqa4JeJcZ4iY130_assertion wasDerivedFrom befree-2016 NP580212.RADVEJ-Geqysg0BWn1lDabLq8O4k10oo-Hqa4JeJcZ4iY130_provenance.
- NP580212.RADVEJ-Geqysg0BWn1lDabLq8O4k10oo-Hqa4JeJcZ4iY130_assertion wasGeneratedBy ECO_0000203 NP580212.RADVEJ-Geqysg0BWn1lDabLq8O4k10oo-Hqa4JeJcZ4iY130_provenance.